RAF265
Total Payments
$16,198
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $16,198 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,198 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR II DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY PK AND PDS OF RAF265 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA | Novartis Pharmaceuticals Corporation | $16,198 | 0 |
Top Doctors Receiving Payments for RAF265
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $16,198 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $16,198
- Total Doctors 0
- Transactions 2
About RAF265
RAF265 is a drug associated with $16,198 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $16,198 was paid across 2 transactions to 0 doctors.
The most common payment nature for RAF265 is "Unspecified" ($16,198, 100.0% of total).
RAF265 is associated with 1 research study, including "A PHASE I AND OR II DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY PK AND PDS OF RAF265 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA" ($16,198).